Inhibikase Therapeutics
IKT
IKT
22 hedge funds and large institutions have $2.49M invested in Inhibikase Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
61% less capital invested
Capital invested by funds: $6.33M → $2.49M (-$3.84M)
Holders
22
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$74.2K | |
| 2 | +$49K | |
| 3 | +$24.9K | |
| 4 |
William Blair & Company
Chicago,
Illinois
|
+$19K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.8K |
Top Sellers
| 1 | -$1.04M | |
| 2 | -$178K | |
| 3 | -$147K | |
| 4 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$103K |
| 5 |
BlackRock
New York
|
-$76K |